The Journal holds the evidence library — 1,500-word trial-cited explainers. The Blog is its faster sibling: market-watch posts, offer teardowns, and pricing-pattern analyses, held to the same honesty rules (verified figures only, claims attributed, disclosure on every commercial page) at shorter length.
Posts
Market watchQ3 2026: where everything stands
Shortage aftermath, the channel war’s repricing, partnership churn, pipeline milestones, and the first generics.
Market watch“Cheapest compounded tirzepatide online”: teardown
What the cheapest-offer search actually surfaces, and how the teaser mechanics work underneath.
How the Blog differs from the Journal
Journal pieces are evidence files — built on named trials and labels, meant to age slowly. Blog posts are timestamped reads on a moving market — meant to be checked against the ledger and its archive as prices drift. When a blog observation hardens into durable guidance, it graduates into the Journal.